A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adults Aged 18 to 65 Years inclusive.

Trial Profile

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adults Aged 18 to 65 Years inclusive.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary)
  • Indications Bacterial meningitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 24 Feb 2014 According to ClinicalTrials.gov record, planned end date changed from 1 May 2014 to 1 Apr 2014.
    • 24 Feb 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top